Clinical trials: Dyskinesia, Drug-Induced
Oral Dystonia, Tardive Dystonia
Dysport for the Treatment of OMD
The purpose of this study is to study the efficacy and safety of AbobotulinumtoxinA (Dysport) for use in Oromandibular Dystonia (OMD).
- Trial name
- NCT01921270
- Testing
- Low Dose - AbobotulinumtoxinA
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Tardive Dyskinesia
Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents
Prospective study to quantify the prevalence of possible tardive dyskinesia (TD) in outpatient psychiatry practices in the United States (US), as well as to describe the associated disease burden in a cohort of patients with one…
- Trial name
- RE-Kinect (NCT03062033)
- Where
- 34 sites in United States
- Volunteers
- 70 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease, Dyskinesia, Drug-Induced
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
The purpose of this study is to generate long-term safety, tolerability and efficacy data for AFQ056 in patients who have participated in and completed any AFQ056 phase II study in PD-LID (Parkinson's disease, L-dopa induced…
- Conditions
- Parkinson Disease, Dyskinesia, Drug-Induced, Levodopa
- Trial name
- NCT01173731
- Testing
- AFQ056
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Tardive Dyskinesia, Tardive Dystonia
Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia
Rationale: Tardive dyskinesia and dystonia (TDD) are severe side effects of dopamine blocking agents, particularly antipsychotics.
- Trial name
- NCT02524886
- Testing
- GPi DBS with Medtronic electorde and Activa PC pulsegenerator
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- GGZ Centraal
Tardive Dyskinesia
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of two doses (50 and 100 mg) of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
- Trial name
- NCT01688037
- Testing
- NBI-98854
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 109 people
- Sponsor
- Neurocrine Biosciences
Tourette Syndrome, Tardive Dyskinesia
Pimavanserin Treatment in TS
This research study is determining if a drug called Pimavanserin if safe and effective in the treatment of the symptoms of Tourette Syndrome.
- Trial name
- NCT04794413
- Testing
- Pimavanserin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Joseph Jankovic
Schizophrenia
Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia
Randomized, controlled, double-blind, two-armed clinical investigation to show the efficacy and safety of transcutaneous vagus nerve stimulation (t-VNS), applied at the left auricle, in schizophrenia.
- Trial name
- 02VNS2009 (NCT01176721)
- Testing
- t-VNS verum
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- cerbomed GmbH
Medication-Induced Dyskinesia
Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia
This is a double-blind, randomized, placebo-controlled Phase 2a study evaluating the safety, tolerability, and preliminary efficacy of up to 2 mg/day (1 mg BID) of NLX-112 versus placebo in patients with moderate to severe L-DOPA…
- Trial name
- NCT05148884
- Testing
- NLX-112
- Where
- 5 sites in Sweden
- Volunteers
- 27 people
- Sponsor
- Neurolixis SAS
Tardive Dyskinesia, Repetitive Transcranial Magnetic Stimulation
Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TD
# Brief Summary (English Version) Tardive Dyskinesia (TD) is a hyperkinetic movement disorder induced by long-term use of dopamine receptor blockers and related drugs.
- Trial name
- NCT07173920
- Testing
- repetitive Transcranial Magnetic Stimulation
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Peking University Sixth Hospital
Dyskinesia, Drug-Induced
Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia
The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia
- Trial name
- NCT00837707
- Testing
- aripiprazole
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
Schizophrenia, Schizoaffective Disorder
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT07105111
- Testing
- Valbenazine
- Where
- 19 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurocrine Biosciences
Dyskinesia, Medication-Induced, Parkinson's Disease
Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS)
This is a randomized sham-controlled double-blind study to test the hypothesis that transcranial static magnetic field stimulation (tSMS) of the motor cortex improves levodopa-induced dyskinesias in patients with Parkinson's…
- Trial name
- NCT02657681
- Testing
- tSMS
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Fundación de investigación HM
Idiopathic Parkinson's Disease, Drug Induced Dyskinesia
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
The study will involve an eighteen-week, double-blind, placebo-controlled parallel designed comparison between add-on topiramate and add-on placebo to stable treatment with amatadine in the treatment of Parkinson's disease (PD)…
- Trial name
- TOP-DYSK (NCT01789047)
- Testing
- Topiramate, Amantadine
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Rush University Medical Center
Akathisia, Drug-Induced, Dyskinesia, Drug-Induced
Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)
This study was designed to determine if preladenant (SCH 420814, MK-3814) can reduce drug-induced involuntary movements in participants with schizophrenia or schizoaffective disorder.
- Conditions
- Akathisia, Drug-Induced, Dyskinesia, Drug-Induced, Parkinsonian Disorders
- Trial name
- NCT00686699
- Testing
- Preladenant
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Tardive Dyskinesia
Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia
The purpose of this study is to evaluate the efficacy and safety of MT-5199 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
- Trial name
- NCT03176771
- Testing
- MT-5199
- Where
- 82 sites in Japan
- Volunteers
- 256 people
- Sponsor
- Tanabe Pharma Corporation
Dyskinesia, Drug-Induced, Parkinson Disease
Investigating the Causal Role of preSMA in Levodopa-induced Dyskinesia in Parkinson's Disease
Using a within-subject cross-over design, we will include 20 patients with Parkinson disease (PD) and peak-of-dose dyskinesia. Patients will be studied after withdrawal from their normal dopaminergic medication.
- Trial name
- NCT03354455
- Testing
- Repetitive transcranial magnetic stimulation
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Danish Research Centre for Magnetic Resonance
Parkinson Disease, Dyskinesia, Medication-Induced
Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia
The aim of the study is to determine potential anti-dyskinetic properties of CPL500036 (PDE10A inhibitor) in Parkinson disease patients suffering from levodopa Induced dyskinesia.
- Trial name
- NCT05297201
- Testing
- CPL500036 - low dose, CPL500036 - high dose
- Where
- 16 sites in Poland, Ukraine
- Volunteers
- 105 people
- Sponsor
- Celon Pharma SA
Tardive Dyskinesia, Intellectual Disability
Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
The goal of this open-label clinical trial is to test the safety and efficacy of valbenazine treatment in patients with Intellectual/Developmental Disability (IDD) who have a diagnosis of Tardive dyskinesia (TD).
- Conditions
- Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
- Trial name
- TD-AIDD (NCT06107829)
- Testing
- Valbenazine Oral Capsule
- Where
- United States
- Sponsor
- Stephen Ruedrich
Parkinson Disease, Dyskinesia, Drug-Induced
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day).
- Conditions
- Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
- Trial name
- NCT04857359
- Testing
- Dipraglurant
- Where
- 41 sites in United States
- Volunteers
- 25 people
- Sponsor
- Addex Pharma S.A.
Parkinson Disease, Dyskinesia, Medication-Induced
AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia
This is a randomized, double-blind, placebo-controlled, crossover, proof-of-concept Phase 2 study to test efficacy and safety of AV-101 (L-4-chlorokynurenine) in Parkinson's Disease subjects with levodopa-induced dyskinesia.
- Conditions
- Parkinson Disease, Dyskinesia, Medication-Induced, L-Dopa Causing Adverse Effects in Therapeutic Use
- Trial name
- NCT04147949
- Testing
- AV-101
- Volunteers
- 20 people
- Sponsor
- VistaGen Therapeutics, Inc.